A new experimental drug called ACF210 significantly protected the heart, kidneys, and liver from damage caused by type 2 diabetes in laboratory mice, according to Gram Research analysis. The drug works through two different pathways simultaneously and reduced dangerous scarring, improved organ function, and controlled blood sugar better than existing single-pathway treatments over a 12-week period. However, this early-stage animal research requires human clinical trials before the drug could become available to patients.
Researchers tested a new experimental drug called ACF210 that works in two ways to fight type 2 diabetes and its complications. According to Gram Research analysis, the drug protected mice from damage to their hearts, kidneys, and livers that normally happens with diabetes. ACF210 combines two different medicines into one treatment that targets multiple organs at once. In 12-week tests, the drug improved blood sugar control better than existing treatments and reduced dangerous scarring in the heart and kidney damage. This research suggests ACF210 could become an important new option for people with type 2 diabetes who develop serious complications affecting multiple organs.
Key Statistics
A 2026 research article found that ACF210, a dual GLP-1/APJ receptor agonist, reduced heart failure biomarkers and prevented cardiac fibrosis in diabetic mice while simultaneously improving kidney function as measured by reduced urinary albumin-to-creatinine ratio.
According to research reviewed by Gram, ACF210 demonstrated superior multi-organ protective effects compared to dulaglutide or Fc-ELA alone, reducing mitochondrial damage, promoting microangiogenesis, and alleviating podocyte damage in kidneys of type 2 diabetic mice.
In a 12-week animal study, ACF210 significantly improved blood glucose control and pancreatic β-cell function while reducing hepatic steatosis and glomerular basement membrane thickening, addressing multiple complications of type 2 diabetes simultaneously.
Research showed ACF210 enhanced diastolic heart function and reduced serum cystatin C levels (a kidney damage marker) in diabetic mice, suggesting the dual-pathway approach protects multiple organs that are typically damaged by type 2 diabetes.
The Quick Take
- What they studied: Whether a new experimental drug called ACF210 could protect the heart, kidneys, and liver from damage caused by type 2 diabetes
- Who participated: Laboratory mice with type 2 diabetes, including genetically modified mice and mice fed a high-fat diet combined with a chemical that causes diabetes
- Key finding: ACF210 significantly reduced blood sugar, prevented heart scarring and damage, reduced kidney damage markers, and improved liver health better than existing diabetes drugs tested
- What it means for you: This early-stage research suggests a new treatment approach may eventually help people with type 2 diabetes avoid serious heart, kidney, and liver complications. However, this was animal research, and human testing would be needed before any new treatment becomes available
The Research Details
Scientists created a new experimental drug by combining two different medicines into one molecule. They engineered ACF210 by attaching two active drug components to a protein scaffold (IgG4 Fc fragment) that helps the medicine stay in the body longer. First, they tested in laboratory dishes whether ACF210 could activate the right targets on cells. Then they gave the drug to mice with type 2 diabetes for 12 weeks and compared results to mice receiving existing diabetes drugs or no treatment.
The researchers measured many different health markers in the mice, including blood sugar levels, heart function, kidney function, liver health, and specific proteins that indicate organ damage. They also examined tissue samples under microscopes to see if organs showed physical damage or scarring.
Type 2 diabetes often damages multiple organs at the same time—the heart, kidneys, and liver—but current medicines usually only address blood sugar. This study tested whether a drug that works through two different pathways simultaneously could protect all these organs at once, which would be more effective than current treatments that focus on one problem.
This research was conducted in laboratory animals using established models of type 2 diabetes. The study measured many different health markers and examined actual tissue damage, which strengthens the findings. However, animal studies don’t always translate to human results, and the exact sample size of mice wasn’t specified in the abstract. This is early-stage research that would require human clinical trials before the drug could be used in patients.
What the Results Show
ACF210 significantly improved blood sugar control in diabetic mice and enhanced the function of pancreatic beta cells, which are the cells that produce insulin. The drug demonstrated superior protective effects compared to dulaglutide (an existing GLP-1 drug) and Fc-ELA (another experimental component) when tested separately.
In the heart, ACF210 reduced mitochondrial damage (damage to the cell’s energy factories), decreased fibrosis (dangerous scarring), improved how well the heart relaxed between beats, and reduced heart failure markers like NT-proBNP. The drug also promoted the growth of new small blood vessels in the heart, which improves blood flow.
In the kidneys, ACF210 reduced damage to podocytes (specialized kidney cells that filter waste) and prevented thickening of the glomerular basement membrane (a critical filtering structure). Kidney function improved as shown by reduced urinary albumin-to-creatinine ratio (UACR) and lower serum cystatin C levels, both markers of kidney damage.
The drug also reduced fatty liver disease, a common complication of type 2 diabetes.
ACF210 appeared to work through dual activation of GLP-1 and APJ receptor pathways simultaneously, suggesting that targeting both pathways together provides better organ protection than targeting just one. The long-acting formulation (designed to stay in the body longer) may contribute to sustained protective effects over the 12-week study period.
Existing GLP-1 receptor drugs like dulaglutide effectively lower blood sugar but don’t fully protect against heart and kidney damage. This research suggests that adding APJ receptor activation to GLP-1 therapy creates additional protective benefits that neither pathway alone can provide. The combination approach addresses a major limitation of current diabetes treatments.
This study was conducted only in laboratory mice, not humans. The exact number of mice used wasn’t specified. While the findings are promising, animal studies often don’t translate perfectly to human results due to differences in metabolism and physiology. The study lasted 12 weeks, which is relatively short-term. Long-term safety and effectiveness in humans would need to be tested in clinical trials before this drug could be prescribed to patients.
The Bottom Line
This research is too early-stage to recommend ACF210 for patients. People with type 2 diabetes should continue taking their current prescribed medications. However, this research suggests that future treatments combining GLP-1 and APJ receptor activation may offer better protection against multiple organ damage. Discuss any new treatment options with your doctor.
This research is most relevant to people with type 2 diabetes who have developed complications affecting the heart, kidneys, or liver. It’s also important for researchers and pharmaceutical companies developing new diabetes treatments. People currently taking GLP-1 drugs should not change their treatment based on this early research.
This is fundamental research in animals. If results are confirmed in further animal studies, human clinical trials would likely take 3-5 years minimum before any potential approval. Realistic timeline for availability as a treatment: 5-10 years at earliest, if development continues successfully.
Frequently Asked Questions
Can I take ACF210 for my type 2 diabetes right now?
No, ACF210 is still in early research stages tested only in laboratory mice. It has not been tested in humans and is not approved by any regulatory agency. Continue taking your current diabetes medications as prescribed by your doctor.
How does ACF210 work differently than my current GLP-1 medication?
ACF210 activates two different receptor pathways (GLP-1 and APJ) simultaneously, whereas current GLP-1 drugs like dulaglutide only activate one pathway. This dual approach appears to provide better protection against heart, kidney, and liver damage in animal studies.
When might ACF210 become available as a treatment?
If development continues successfully, human clinical trials would likely begin in 2-3 years. Even with successful trials, regulatory approval and availability could take 5-10 years minimum. This timeline assumes no significant setbacks in development.
Does this research mean my current diabetes treatment isn’t good enough?
No. Current GLP-1 drugs effectively lower blood sugar and reduce some complications. This research suggests future treatments might offer additional organ protection, but your current medication remains appropriate. Discuss any concerns with your doctor.
Why is protecting the heart and kidneys important for people with diabetes?
Type 2 diabetes damages multiple organs simultaneously—the heart, kidneys, and liver. Current treatments mainly control blood sugar but don’t fully prevent this organ damage. ACF210’s dual approach attempts to address all three organ systems at once, potentially preventing serious complications.
Want to Apply This Research?
- Track multiple organ health markers: daily blood glucose readings, weekly weight, monthly blood pressure, and quarterly kidney function tests (if available through your healthcare provider). Note any changes in energy levels, shortness of breath, or swelling that might indicate heart or kidney issues.
- Use the app to set reminders for taking current diabetes medications consistently, log meals to monitor carbohydrate intake, and record exercise sessions. These behaviors directly support heart, kidney, and liver health while waiting for new treatment options to potentially become available.
- Create a long-term health dashboard tracking blood sugar trends, weight changes, blood pressure patterns, and any kidney function markers your doctor provides. Set quarterly check-in reminders to review trends with your healthcare provider and discuss whether your current treatment plan needs adjustment.
This article discusses early-stage laboratory research in animals. ACF210 has not been tested in humans and is not approved for any medical use. This research should not be interpreted as medical advice or a recommendation to change your current diabetes treatment. People with type 2 diabetes should continue taking medications prescribed by their healthcare provider and discuss any questions about new treatments with their doctor. This article is for educational purposes only and does not replace professional medical consultation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.